Fabio Cataldi

Dr. Cataldi has over twenty years of diverse and extensive experience in medicine and drug development in the United States and Italy. He most recently served as Vice President and Therapeutic Area Head of Gastroenterology at Arena Pharmaceuticals, where he led the development of etrasimod in inflammatory bowel disease (IBD) and other gastrointestinal (GI) indications and expanded the immunology portfolio. Prior to joining Arena Pharmaceuticals, Dr. Cataldi served as Team Lead of Gastroenterology and Immunology in Global Pharmaceutical Research and Development at AbbVie. Previously, Dr. Cataldi worked at Shire as Vice President of Clinical Development in Internal Medicine/Gastroenterology, where he led the expansion of the IBD portfolio with the out licensing of the anti-MAdCAM antibody from Pfizer. Before Shire, Dr. Cataldi served as Pfizer’s Senior Director of Gastroenterology Biotherapeutics Clinical Programs in Worldwide R&D, where he led the expansion of the Immunology and GI portfolio with assets targeting multiple diseases beyond IBD, including rheumatoid arthritis, systemic lupus erythematosus and dermatology conditions. Earlier in his career, Dr. Cataldi held roles at: Biogen Idec, where he oversaw the approval and launch of Tysabri in Crohn’s Disease; Novartis, where he supported the launch of Zelnorm for treatment of irritable bowel syndrome with constipation; Solvay Pharmaceuticals, where he helped with the New Drug Admission process with the U.S. Food and Drug Administration for Creon; and Beth Israel Deaconess Medical Center in Boston, MA.

Dr. Cataldi holds an MD from the Second University of Naples (SUN) in Medicine and Surgery.